{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:17:48Z","timestamp":1780679868310,"version":"3.54.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Posthoc analysis of the MORE osteoporosis treatment trial assessed risk-benefit profile of raloxifene in 7705 postmenopausal women. A major disease outcomes global index resulted in annual rates of 1.39% and 1.83% in the raloxifene and placebo groups, respectively (HR, 0.75; 95% CI, 0.62-0.92), compatible with a favorable risk-benefit profile for raloxifene for treating postmenopausal osteoporosis.<\/jats:p>\n               <jats:p>Introduction: The Women's Health Initiative (WHI) trial reported overall risks that exceeded benefits from use of estrogen-progestin in healthy postmenopausal women. The objective of this posthoc analysis of the Multiple Outcomes of Raloxifene Evaluation (MORE) trial was to assess the safety profile of raloxifene, a selective estrogen receptor modulator indicated for the prevention and treatment of osteoporosis, using the global index method from the WHI trial.<\/jats:p>\n               <jats:p>Materials and Methods: A total of 7705 postmenopausal women (mean age, 67 years) were enrolled in the MORE osteoporosis treatment trial and randomly assigned to receive placebo or one of two doses of raloxifene (60 or 120 mg\/day) for 4 years. A global index of clinical outcomes, defined as described for the WHI trial (the earliest occurrence of coronary heart disease, stroke, pulmonary embolism, invasive breast cancer, endometrial cancer, colorectal cancer, hip fracture, or death because of other causes) was applied to the MORE trial data. Physicians blinded to treatment assignment adjudicated events. Intention-to-treat survival analysis of time-to-first-event was performed using a proportional hazards model.<\/jats:p>\n               <jats:p>Results and Conclusions: The annualized rate of global index events was 1.83% in the placebo group and 1.39% in the combined raloxifene dose groups (hazard ratio [HR], 0.75; 95% CI, 0.62-0.92). Analyzing individual dose groups separately yielded the same results (HR for 60 mg\/day, 0.75; 95% CI, 0.60-0.96: HR for 120 mg\/day, 0.75; 95% CI, 0.59-0.95). Subgroup analyses showed no significant interactions between age or hysterectomy status and the effect of raloxifene on the global index (interaction p &amp;gt; 0.1), whereas the global index risk reduction seemed to be greater in obese women compared with nonobese women (interaction p = 0.03). The significant 25% reduction in global index is compatible with a favorable risk-benefit safety profile when raloxifene is used for osteoporosis treatment in postmenopausal women. These results require confirmation in ongoing clinical trials.<\/jats:p>","DOI":"10.1359\/jbmr.040406","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:44:52Z","timestamp":1146098692000},"page":"1270-1275","source":"Crossref","is-referenced-by-count":66,"title":["Risk-Benefit Profile for Raloxifene: 4-Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial"],"prefix":"10.1093","volume":"19","author":[{"given":"Elizabeth","family":"Barrett-Connor","sequence":"first","affiliation":[{"name":"Division of Epidemiology, Department of Family and Preventive Medicine, University of California at San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A","family":"Cauley","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pandurang M","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Sashegyi","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Cox","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Geiger","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024013019193334400_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Writing Group for the Women's Health Initiative Investigators","year":"2002","journal-title":"JAMA"},{"key":"2024013019193334400_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0197-2456(96)00016-5","article-title":"Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women's Health Initiative","volume":"17","author":"Freedman","year":"1996","journal-title":"Control Clin Trials"},{"key":"2024013019193334400_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"2024013019193334400_bib4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.288.7.872","article-title":"Postmenopausal hormone replacement therapy: Scientific review","volume":"288","author":"Nelson","year":"2002","journal-title":"JAMA"},{"key":"2024013019193334400_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"2024013019193334400_bib6","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1001\/archinte.160.22.3444","article-title":"Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women. 3-year data from two double-blind, randomized, placebo-controlled trials","volume":"160","author":"Johnston","year":"2000","journal-title":"Arch Intern Med"},{"key":"2024013019193334400_bib7","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"2024013019193334400_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"2024013019193334400_bib9","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019193334400_bib10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jama.287.7.847","article-title":"Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial","volume":"287","author":"Barrett-Connor","year":"2002","journal-title":"JAMA"},{"key":"2024013019193334400_bib11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1006\/gyno.2001.6578","article-title":"The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women","volume":"85","author":"Neven","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"Suppl","key":"2024013019193334400_bib12","first-page":"179","article-title":"NOVACODE serial ECG classification system for clinical trials and epidemiologic studies","volume":"24","author":"Rautaharju","year":"1992","journal-title":"J Electrocardiol"},{"key":"2024013019193334400_bib13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/0895-4356(95)00516-1","article-title":"A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. Description and validation of methods. World Health Organization Collaborative Study of Cardiovascular and Steroid Hormone Contraception","volume":"48","author":"World Health Organization","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"2024013019193334400_bib14","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"2024013019193334400_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/01.STR.32.1.47","article-title":"Bone mineral density in acute stroke patients: Low bone mineral density may predict first stroke in women","volume":"32","author":"Jorgensen","year":"2001","journal-title":"Stroke"},{"key":"2024013019193334400_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s002239900419","article-title":"Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women","volume":"62","author":"Barengolts","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"2024013019193334400_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00223-002-2070-x","article-title":"Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women","volume":"73","author":"Tanko","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"2024013019193334400_bib18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/0003-4819-130-4_Part_1-199902160-00004","article-title":"Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group","volume":"130","author":"Cauley","year":"1999","journal-title":"Ann Intern Med"},{"key":"2024013019193334400_bib19","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1200\/JCO.2001.19.12.3111","article-title":"Indicators of lifetime estrogen exposure: Effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants","volume":"19","author":"Lippman","year":"2001","journal-title":"J Clin Oncol"},{"key":"2024013019193334400_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jama.287.2.216","article-title":"Serum estradiol level and risk of breast cancer during treatment with raloxifene","volume":"287","author":"Cummings","year":"2002","journal-title":"JAMA"},{"key":"2024013019193334400_bib21","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa030311","article-title":"Effects of estrogen plus progestin on health-related quality of life","volume":"348","author":"Hays","year":"2003","journal-title":"N Engl J Med"},{"key":"2024013019193334400_bib22","first-page":"359","article-title":"Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: A placebo-controlled randomized trial","volume":"96","author":"Strickler","year":"2000","journal-title":"Obstet Gynecol"},{"key":"2024013019193334400_bib23","author":"National Cancer Institute","year":"2000"},{"key":"2024013019193334400_bib24","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/jnci\/91.24.2102","article-title":"Beta-carotene supplementation and incidence of cancer and cardiovascular disease: The Women's Health Study","volume":"91","author":"Lee","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"2024013019193334400_bib25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"2024013019193334400_bib26","doi-asserted-by":"crossref","first-page":"933","DOI":"10.7326\/0003-4819-133-12-200012190-00008","article-title":"A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease","volume":"133","author":"Grodstein","year":"2000","journal-title":"Ann Intern Med"},{"key":"2024013019193334400_bib27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0002-9149(01)01685-X","article-title":"Design and methods of the Raloxifene Use for The Heart (RUTH) study","volume":"88","author":"Mosca","year":"2001","journal-title":"Am J Cardiol"},{"key":"2024013019193334400_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3816\/CBC.2002.n.020","article-title":"The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial","volume":"3","author":"Vogel","year":"2002","journal-title":"Clin Breast Cancer"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.040406","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/8\/1270\/56473289\/5650190809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/8\/1270\/56473289\/5650190809.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:06:54Z","timestamp":1710342414000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/19\/8\/1270-1275\/7592656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,1]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2004,8,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.040406","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,8,1]]},"published":{"date-parts":[[2004,8,1]]}}}